Oric Pharmaceuticals Inc (ORIC) - Net Assets
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has net assets worth $415.56 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($436.76 Million) and total liabilities ($21.20 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ORIC intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $415.56 Million |
| % of Total Assets | 95.14% |
| Annual Growth Rate | 40.22% |
| 5-Year Change | 40.8% |
| 10-Year Change | N/A |
| Growth Volatility | 159.63 |
Oric Pharmaceuticals Inc - Net Assets Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See ORIC days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual net assets of Oric Pharmaceuticals Inc from 2017 to 2025. For live valuation and market cap data, see market value of Oric Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $384.36 Million | +58.09% |
| 2024-12-31 | $243.12 Million | +8.49% |
| 2023-12-31 | $224.09 Million | +0.78% |
| 2022-12-31 | $222.35 Million | -18.55% |
| 2021-12-31 | $272.98 Million | -5.80% |
| 2020-12-31 | $289.78 Million | +229.39% |
| 2019-12-31 | $87.97 Million | +236.55% |
| 2018-12-31 | $-64.43 Million | -350.43% |
| 2017-12-31 | $25.73 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Oric Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 64779800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Comprehensive Income | $786.00K | 0.20% |
| Other Components | $1.08 Billion | 279.89% |
| Total Equity | $384.36 Million | 100.00% |
Oric Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Amerigo Resources Ltd.
TO:ARG
|
$828.17 Million |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
$828.23 Million |
|
Ton Yi Industrial Corp
TW:9907
|
$828.37 Million |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
$828.43 Million |
|
Abacus Life Inc.
NASDAQ:ABL
|
$827.97 Million |
|
MBK Public Company Limited
BK:MBK
|
$827.68 Million |
|
Xencor Inc
NASDAQ:XNCR
|
$827.65 Million |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
$827.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oric Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 243,122,000 to 384,362,000, a change of 141,240,000 (58.1%).
- Net loss of 129,468,000 reduced equity.
- New share issuances of 244,369,000 increased equity.
- Other comprehensive income increased equity by 407,000.
- Other factors increased equity by 25,932,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-129.47 Million | -33.68% |
| Share Issuances | $244.37 Million | +63.58% |
| Other Comprehensive Income | $407.00K | +0.11% |
| Other Changes | $25.93 Million | +6.75% |
| Total Change | $- | 58.09% |
Book Value vs Market Value Analysis
This analysis compares Oric Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.97x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.47x to 1.97x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $18.24 | $8.63 | x |
| 2018-12-31 | $-37.15 | $8.63 | x |
| 2019-12-31 | $2.94 | $8.63 | x |
| 2020-12-31 | $13.21 | $8.63 | x |
| 2021-12-31 | $7.19 | $8.63 | x |
| 2022-12-31 | $5.61 | $8.63 | x |
| 2023-12-31 | $4.36 | $8.63 | x |
| 2024-12-31 | $3.49 | $8.63 | x |
| 2025-12-31 | $4.38 | $8.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oric Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.07x
- Recent ROE (-33.68%) is above the historical average (-37.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -85.63% | 0.00% | 0.00x | 1.17x | $-24.60 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.92 Million |
| 2019 | -30.56% | 0.00% | 0.00x | 1.07x | $-35.68 Million |
| 2020 | -25.43% | 0.00% | 0.00x | 1.03x | $-102.68 Million |
| 2021 | -28.46% | 0.00% | 0.00x | 1.09x | $-104.97 Million |
| 2022 | -40.08% | 0.00% | 0.00x | 1.13x | $-111.36 Million |
| 2023 | -44.94% | 0.00% | 0.00x | 1.14x | $-123.11 Million |
| 2024 | -52.59% | 0.00% | 0.00x | 1.13x | $-152.16 Million |
| 2025 | -33.68% | 0.00% | 0.00x | 1.07x | $-167.90 Million |
Industry Comparison
This section compares Oric Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc (ORIC) | $415.56 Million | -85.63% | 0.05x | $828.14 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more